...
首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >Role of antihypertensives drugs on proteinuria in patients with chronic kidney disease and hypertension
【24h】

Role of antihypertensives drugs on proteinuria in patients with chronic kidney disease and hypertension

机译:降压药对慢性肾脏病和高血压患者蛋白尿的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Hypertension is the most prevalent cardiovascular disease and the relevant data suggest that the burden, risk factors and co-morbidities associated with the essential hypertension is increasing with every passing day. It is one of the major chronic diseases resulting in high mortality and morbidity in today’s world. Aim: The aim of the study was to compare effects of cilnidipine and amlodipine on the blood pressure (BP), heart rate and proteinuria among patients of hypertension with chronic kidney disease. Methods: 100 patients were included in this study. Patients were randomly assigned into two groups Group A and Group B (50 each). Group A: Patients received Cilnidipine (5-10mg/day). Group B: Patients received amlodipine (5-10mg/day). Results: No significant difference in SBP, DBP, MBP and proteinuria while comparing both the groups of patients taking cilnidipine and amlodipine at baseline i.e. 0 to 12 week, 12 to 24 weeks and 0 to 24 weeks. Cilnidipine caused decrease in HR 0 to 12 week (p value 0.001), 12 to 24 weeks (p value 0.001) and 0 to 24 weeks (p value 0.0001). Amlodipine had increased heart rate from baseline to 12 weeks (p value 0.0001), 12 to 24 weeks (p value 0.051) and 0 to 24 weeks (p value 0.001). No significant difference was seen in any biochemical readings. Conclusions: There was a significant change in all the parameters including BP, heart rate, proteinuria and other biochemical tests when they compared within the group but no significant difference while comparing both the groups.
机译:背景:高血压是最普遍的心血管疾病,相关数据表明,与原发性高血压相关的负担,危险因素和合并症随着日趋增加。它是导致当今世界高死亡率和高发病率的主要慢性疾病之一。目的:本研究的目的是比较西尼地平和氨氯地平对慢性肾脏病高血压患者血压,心率和蛋白尿的影响。方法:本研究纳入100例患者。将患者随机分为A组和B组两个组(每组50个)。 A组:患者接受西尼地平(5-10mg /天)。 B组:患者接受氨氯地平(5-10mg /天)。结果:在基线时(即0至12周,12至24周和0至24周)比较西尼地平和氨氯地平的两组患者的SBP,DBP,MBP和蛋白尿无显着差异。西尼地平导致HR降低0至12周(p值0.001),12至24周(p值0.001)和0至24周(p值0.0001)。氨氯地平的心率从基线增加到12周(p值0.0001),12到24周(p值0.051)和0到24周(p值0.001)。在任何生化读数中均未见明显差异。结论:当在组内进行比较时,包括BP,心率,蛋白尿和其他生化检查在内的所有参数均发生了显着变化,而在两组之间进行比较时则无显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号